期刊文献+

应用Sonoclot体外监测低分子肝素及磺达肝癸钠的抗凝作用 被引量:2

Anticoagulation effects of low molecular heparin and fondaparinux in vitro by the Sonoclot analyzer
下载PDF
导出
摘要 目的:探讨Sonoclot凝血仪在分析监测凝血与血小板功能的临床价值。方法:在gb试剂杯加入不同浓度的低分子肝素钠(0~1.6 IU/mL抗Xa因子)、低分子肝素钙(0~1.64 IU/mL抗Xa因子)、磺达肝癸钠(0~1.52μg/mL),抽取10例健康志愿者血样,并加入有药物的试剂杯中,用Sonoclot凝血仪进行检测,检测指标分别包括激活凝血时间(ACT)、凝血速率(CR)和血小板功能(PF)。结果:(1)3种抗凝药物随着浓度的增加,其ACT值逐渐增加,CR值逐渐下降,PF值逐渐下降。(2)对于同一治疗量的3种抗凝药物,低分子肝素钠(1.2 IU/mL抗Xa因子)与低分子肝素钙(1.23 IU/mL抗Xa因子),其ACT、CR、PF 3个参数的比较,P>0.05,无统计学差异。磺达肝癸钠(0.77μg/mL)与低分子肝素钠(1.2 IU/mL抗Xa因子)和低分子肝素钙(1.23 IU/mL抗Xa因子)相比,其ACT、CR、PF 3个参数均有差异性,均P<0.01。结论:Sonoclot凝血仪可以快速检测低分子肝素及磺达肝癸钠的抗凝效果以及对于血小板功能的影响,可以对临床给药剂量和个体化治疗做出指导。 Objective: To examine the Sonoclot analyzer's capability and in monitoring the blood coagulation and platelet function in vitro and evaluate its practical clinical significance. Methods: The blood samples were taken from 10 healthy volunteers after 1 h break. The samples were added into the gb cups in which different concentrations of low-molecular-weight heparin sodium (LHWHs)(0-1.6 IU/mL anti-Xa factor), low-molecular-weight beparin ealcium(LHWHc) (0-1.64 IU/mL anti-Xa factor ) and fondaparinux (0 -1.52μg/mL) were added respectively in advance. The ACT, CR and PF were tested by the Sonoclot anaylzer. Results: (1) ACT in three groups increased sig- nificantly(P〈0.01) with the increasing concentration of LMWHs, LMWHc and fondaparinux. CR and PF decreased signifieantly(P〈0.01) with the increasing concentration of LMWHs, LMWHc and fondaparinux. (2)There was no significant difference between the LMWHs (1.2 IU/mL anti-Xa factor) and LMWHc (1.23 IU/mL anti-Xa factor) grouplin terms of the ACT and PF (P〉0.05) in the concentration(1.2 IU/ mL LMWHs and 1.23 IU/mL LMWHc). There was significant difference between fondaparinux (0.77μg/mL) LMWHs(1.2 IU/mL anti-Xa factor) and LMWHc(1.23 IU/mL anti-Xa factor) with respect to ACT, CR and PF(P〈0.01). Conclusion: Sonoclot analyzer can quickly de- tect low-molecular-weight heparin and fondaparinux anticoagulation effect and the platelet function, it can be reliable in providing guid- ance for clinical dose and individual treatment.
出处 《天津医科大学学报》 2012年第2期217-220,共4页 Journal of Tianjin Medical University
关键词 Sonoclot凝血仪 凝血功能 血小板功能 低分子肝素钠 磺达肝癸钠 低分子肝素钙 Sonoclot coagulation analyzer coagulation platelet function low-molecular-weight heparin sodium fondaparinux low-molecular-weight heparin calcium
  • 相关文献

参考文献10

二级参考文献107

  • 1尹明.降纤酶联用低分子肝素治疗心肌梗死5例临床观察[J].中国中西医结合急救杂志,2005,12(4):247-247. 被引量:1
  • 2Harenberg J.Is laboratory monitoring of low-molecularweight heparin therapy necessary? Yes.J Thromb Haemost 2004; 2:547-550.
  • 3Bounameaux H,de Moerloose P.Is laboratory monitoring of low molecular-weight heparin therapy necessary? No.J Thromb Haemost 2004; 2:551-554.
  • 4Milovic NM,Behr JR,Godin M,Hou CS,Payer KR,Chandrasekaran A,et al.Monitoring of heparin and its low-molecular-weight analogs by silicon field effect.Proc Nail Acad Sci U S A 2006; 103:13374-13379.
  • 5Middeldorp S.Heparin:from animal organ extract to designer drug.Thromb Res 2008; 122:753-762.
  • 6Clem JR.Anti-factor Xa levels:when should they be used? S D Med 2006; 59:261-262.
  • 7Fergnson J J,Califf RM,Antman EM,Cohen M,Grines CL,Goodman S,et al.SYNERGY Trial Investigators.Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy:primary results of the SYNERGY randomized trial.JAMA 2004; 292:45-54.
  • 8White HD,Kleiman NS,Mahaffey KW,Lokhnygina Y,Pieper KS,Chiswell K,et al.Efficacy and safety of enoxaparin compared with unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention in the Superior Yield of the New Strategy of Enoxaparin,Revascularization and Glycoprotein Ⅱb/Ⅲa Inhihitors (SYNERGY) trial.Am Heart J 2006; 52:1042-1050.
  • 9Blazing MA,de Lemos JA,White HD,Fox KA,Verheugt FW,Ardissino D,et al.Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin:a randomized controlled trial.JAMA 2004; 292:55-64.
  • 10Lepor NE.Anticoagnlation for acute coronary syndromes:from heparin to direct thrombin inhibitors.Rev Cardiovasc Med 2007; 8 Suppl 3:S9-S17.

共引文献53

同被引文献32

  • 1宋莉,颜红兵.磺达肝癸钠在急性冠脉综合征治疗中的应用[J].中国心血管病杂志,2010,38(5):471.
  • 2杨超,李彦,杨永忠.磺达肝癸钠对非ST段抬高急性冠脉综合征的疗效与安全性的研究[J].药物与临床,2013,10(3):91-95.
  • 3PHAM P A,PHAM P T,PHAM P C,et al. Implica- tions of bleeding in acute coronary syndrome and per- cutaneous coronary intervention[J]. Vasc Health Risk Manag,2011,7:551- 567.
  • 4DAVIDSON S J,WADHAM P,ROGERS L,et al. En- dothelial cell damage in heparin-induced thrombocyto- penia[J]. Blood Coagul Fibrinolysis, 2007,18 ( 4 ) : 317 -320.
  • 5WARKENTIN T E. HIT paradigms and paradoxes [J]. J Thromb Haemost,2011,9:105-117.
  • 6WARKENTIN T E, DAVIDSON B L, BULLER H R,et al. Prevalence and risk of preexisting heparin-in-duced thrombocytopenia antibodies in patients with a- cute VTE[J]. Chest, 2011,140 : 366 - 373.
  • 7LEVINE R L, HERGENROEDER G W, FRANCIS J L,et al. Heparin-platelet factor 4 antibodies in inten- sive care patients: an observational seroprevalenee study[J]. J Thromb Thrombolysis, 2010, 30:142 - 148.
  • 8HANNA E B,GLANCY D L,SAUCEDO J F. Anti- platelet and anticoagulant therapies in acute coronary syndromes[J]. Cardiovase Drugs Ther, 2010,24 : 61 - 70.
  • 9SALEM M,ELREFAI S,SHRIT M A,et al. Fondapa- rinux thromboprophylaxis-associated heparin-induced thrombocyto-penia syndrome complicated by arterial thrombotic stroke [J]. Thromb Haemost, 2010, 104 : 1071-1072.
  • 10VAN REES VELL1NGA T E,PETERS R J ,YUSUF S, et al. Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organiza- tion for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial[J]. Am Heart J,2010, 160:1049-1055.

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部